Found: 11
Select item for more details and to access through your institution.
Front & Back Matter.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 1, doi. 10.1159/000533455
- Publication type:
- Article
Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 189, doi. 10.1159/000531225
- By:
- Publication type:
- Article
Genomic and Immune Features in an Intrahepatic Cholangiocarcinoma Patient with Microsatellite Instability-High Suffered Rapid Acquired Resistance to PD-1 Inhibitor.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 198, doi. 10.1159/000530134
- By:
- Publication type:
- Article
Efficacy of Local Treatment in Lymph Node Metastasis from Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 218, doi. 10.1159/000529201
- By:
- Publication type:
- Article
Trends and Disparities in Stage-Specific Incidence of Hepatocellular Carcinoma among US Adults, 2004–2019.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 277, doi. 10.1159/000528374
- By:
- Publication type:
- Article
Outcomes of Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma Converted by Transcatheter Arterial Chemoembolization Combined with Lenvatinib plus Anti-PD-1 Antibodies: A Multicenter Retrospective Study.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 229, doi. 10.1159/000528356
- By:
- Publication type:
- Article
IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 238, doi. 10.1159/000528272
- By:
- Publication type:
- Article
Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 251, doi. 10.1159/000528145
- By:
- Publication type:
- Article
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 262, doi. 10.1159/000528034
- By:
- Publication type:
- Article
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 3, p. 209, doi. 10.1159/000527402
- By:
- Publication type:
- Article